(Alliance News) - Sanofi SA and GlaxoSmithKline PLC's adjuvanted recombinant Covid-19 vaccine candidate achieved strong rates of neutralizing antibody responses, the companies reported on Monday.
The interim results showed 95% to 100% seroconversion following a second injection in patients from 18 to 95 years old and across all doses, with acceptable tolerability and with no safety concerns. Overall, the vaccine candidate elicited strong neutralizing antibody levels that were comparable to those generated by natural infection.
The results came from a phase 2 study in all adult age groups with 722 volunteers. A global pivotal phase 3 study is expected to start in the coming weeks, the pharmaceutical companies said.
"Our phase 2 data confirm the potential of this vaccine to play a role in addressing this ongoing global public health crisis, as we know multiple vaccines will be needed, especially as variants continue to emerge and the need for effective and booster vaccines, which can be stored at normal temperatures, increasesâ€, said Thomas Triomphe, executive vice president & global head of Sanofi Pasteur.
"[We] will move to phase 3 as soon as possible to meet our goal of making it available before the end of the year," added Roger Connor, president of GSK Vaccines.
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Glaxosmithkline (GSK)
